August 2026 FDA Warning Letters to Peptide Sellers: How “Research Use Only” Is Being Read

“For research use only” is the phrase that allows a peptide to be sold outside the drug-approval system. It is also the phrase regulators scrutinize most closely, because it means nothing if the rest of a seller’s conduct contradicts it. In late August 2026, FDA made that point in writing to four companies at once. The letters are short, procedural documents, but they set out, in the agency’s own words and with quotations from the sellers’ own websites, precisely what conduct converts a research reagent into an unapproved drug in FDA’s view. For a supplier that actually operates on the research side of the line, they are worth reading closely, and this note walks through them.

The four letters

All four letters carry the date August 24, 2026 and were posted to FDA’s warning-letter database on September 1, 2026, each under the subject “Unapproved New Drugs/Misbranded.” The recipients were Peptide Partners LLC of Sarasota, Florida; TXP Innovations LLC, doing business as Tex Peptides, of Dallas; Royal Peptides LLC of Boynton Beach, Florida; and NuScience Peptides LLC of Cornelius, North Carolina.^1,2,3,4

The product lists overlap heavily. Every letter names semaglutide and tirzepatide products sold under GLP-1-style trade names, and a product described as a triple GLP-1/GIP/glucagon receptor agonist. Three of the four name tesamorelin, SS-31 (elamipretide) and PT-141 (bremelanotide). NuScience’s letter adds survodutide and mazdutide. Three letters also name the company’s bacteriostatic water, sold as a “reconstitution solution”, as itself an unapproved drug in this context.^1–4

Recipient	Location	Products cited (summarized)	Conduct FDA relied on
Peptide Partners LLC	Sarasota, FL	Semaglutide, tirzepatide, a triple GLP-1/GIP/glucagon agonist, SS-31, tesamorelin, PT-141, bacteriostatic water	Disease claims (diabetes, obesity, Alzheimer’s, cancer); marketing reconstitution materials for injection
TXP Innovations LLC dba Tex Peptides	Dallas, TX	Same seven categories	Mechanistic claims tied to diabetes and obesity management; bacteriostatic water sold alongside peptides
Royal Peptides LLC	Boynton Beach, FL	Tirzepatide, semaglutide, a triple agonist, SS-31, PT-141, tesamorelin, “BIMORELIN”	Claims of body-weight reduction, glucose control, sexual-dysfunction treatment; bacteriostatic water plus a “peptide guide” and calculator
NuScience Peptides LLC	Cornelius, NC	Tirzepatide, semaglutide, a triple agonist, survodutide, mazdutide, PT-141, tesamorelin variants, bacteriostatic water	References to “therapeutic applications,” weight loss and treating metabolic disorders despite “laboratory, research, and analytical use” labels

The legal theory in each letter

The letters follow one template. FDA asserts that the products are drugs under section 201(g) of the Federal Food, Drug, and Cosmetic Act because they are intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or function of the body. Because they are drugs and are not generally recognized as safe and effective for their labeled uses, they are “new drugs” under section 201(p), and introducing a new drug into interstate commerce without an approved application violates section 505(a).¹

The pivot in every letter is the word “intended.” FDA does not dispute that the labels said “for research use only” or “not for human or veterinary use.” It states that “evidence obtained from your website establishes that your products are intended to be drugs for human use,” and then quotes that evidence.^3,4 This is the long-standing intended-use doctrine: intended use is determined objectively, from labeling, advertising, and the circumstances surrounding distribution, not from a disclaimer alone.⁵

What FDA treated as evidence of human intended use

Read together, the letters give a fairly complete list of the conduct FDA considers disqualifying. It falls into three groups.

Therapeutic and mechanistic claims

The most direct evidence was disease language. Peptide Partners’ site contained statements about treating diabetes, obesity, Alzheimer’s disease and cancer.¹ Royal Peptides referred to “body weight reduction,” “glucose control” and treatment of sexual dysfunction.³ Tex Peptides’ product page said a product “enhances insulin secretion, suppresses glucagon release, and slows gastric emptying” in the context of diabetes and obesity management.² That last example is instructive: it is an accurate description of GLP-1 receptor pharmacology, of the kind found in any review article. What made it a drug claim, in FDA’s reading, was framing it as what the product does for the buyer rather than what the literature reports in defined models.

Furnishing the means of administration

Three letters treat the sale of bacteriostatic water alongside peptides as evidence in itself. Tex Peptides’ letter states that offering bacteriostatic water with the peptides demonstrated intent for injectable human administration rather than research.² Royal Peptides went further, providing “bacteriostatic water alongside a peptide guide and peptide calculator,” which FDA characterized as furnishing the means for preparing an injectable drug.³ Bacteriostatic water has legitimate laboratory uses, see what bacteriostatic water is and why labs use it, but bundled with a dosing calculator it reads, to FDA, as an administration kit.

Labels that contradict the marketing

NuScience’s letter is the clearest on this point. Its products were labeled “for laboratory, research, and analytical use” and “not intended for human or veterinary use,” and FDA quoted those phrases immediately before quoting the site’s references to “therapeutic applications” and “weight loss.”⁴ The juxtaposition is the argument: a label cannot disclaim what the surrounding pages assert.

A research-use-only label describes a seller’s obligations; it does not discharge them.

Why the product mix matters

The letters are notable for what they target. The bulk of the cited products are incretin-class peptides, semaglutide and tirzepatide, which are the active ingredients of approved drugs, and investigational multi-agonists such as survodutide, mazdutide and a triple GLP-1/GIP/glucagon agonist that are in or emerging from phase 3 trials. This is consistent with FDA’s stated priorities in 2026. In February the agency announced it would act against non-approved GLP-1 products being mass-marketed as alternatives to approved drugs, including by restricting access to the active ingredients, and warned that “failure to adequately address any violations may result in legal action without further notice.”⁶ In April it proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List permanently.⁷ The August letters extend the same enforcement logic from compounders and telehealth platforms to research-labeled sellers whose marketing made the same weight-loss promises. Wednesday’s note on the 2026 GLP-1 compounding rule covers that side of the story.

The GH-axis peptide tesamorelin also appears in three of four letters. Tesamorelin is the active ingredient of an approved drug for a specific HIV-associated indication, which means unapproved versions marketed with body-composition language face the same “new drug” analysis. Research-grade tesamorelin is not the approved product; see the tesamorelin research overview.

What FDA asked for

Each letter requests a written response within fifteen business days describing the steps taken to correct the violations, the root cause, and the measures put in place to prevent recurrence, with supporting documentation.^1–4 A warning letter is not itself a penalty. It is a formal notice that the agency believes violations exist and an opportunity to correct them; failure to respond adequately can lead to seizure, injunction or other action. Whether any of the four companies has responded is not public as of this writing.

What a research supplier takes from this

The letters are effectively a checklist, drawn from FDA’s own reasoning, of what a supplier operating on the research side of the line does not do. It does not describe products in terms of what they will do for a person. It does not attach disease names to product pages. It does not publish dosing calculators, “guides” to preparation, or sell solvent bundled with peptides in a way that reads as a kit. It does describe the literature accurately, what was observed in a rat tendon model, or in a phase 2 trial of an approved pharmaceutical version, and it distinguishes explicitly between preclinical and clinical evidence and between research-grade material and any approved drug. Wednesday’s note on what “research use only” means and the catalog guide set out how that policy is applied on this site.

The broader point is that FDA is reading websites, not just labels, and in 2026 it is reading them with particular attention to incretin-class peptides. A research library that reports the science plainly, cites its sources and avoids human-use framing is not only good practice; on the evidence of these four letters, it is the difference the agency is looking for.

Frequently asked questions

Are research use only peptides legal to sell in the United States?

A peptide sold genuinely for laboratory research, without claims or conduct indicating human use, is not regulated as a drug. The August 2026 letters show that FDA determines intended use from a seller’s total conduct, website claims, bundled supplies, guides and calculators, not from the label alone. Where that conduct indicates human use, FDA treats the product as an unapproved new drug.

Which companies received FDA warning letters for peptides in August 2026?

Peptide Partners LLC, TXP Innovations LLC (Tex Peptides), Royal Peptides LLC and NuScience Peptides LLC. All four letters are dated August 24, 2026 and were posted on September 1, 2026 under the subject “Unapproved New Drugs/Misbranded.”

Why did FDA cite bacteriostatic water as a drug?

Because of context. Sold on its own, bacteriostatic water is a laboratory reagent. Sold alongside injectable peptides, a reconstitution guide and a dosing calculator, FDA concluded it was being furnished as the means to prepare an injectable drug for human use, and it cited the water as part of the unapproved-drug offering.

Does a warning letter mean the products were unsafe or fake?

No. These letters make no findings about product quality, purity or adverse events. They concern intended use and the absence of FDA approval. Product quality is a separate question addressed by batch-specific third-party testing.

Did these letters involve BPC-157 or TB-500?

Not in this group. The August 2026 letters focused on GLP-1-class peptides, tesamorelin, SS-31, PT-141 and bacteriostatic water. Earlier FDA letters in 2025 did address BPC-157 and other peptides sold as research use only with contradictory marketing.

References & further reading

1. U.S. Food and Drug Administration, CDER. Warning Letter: Peptide Partners LLC (735063). August 24, 2026. fda.gov
2. U.S. Food and Drug Administration, CDER. Warning Letter: TXP Innovations LLC dba Tex Peptides (735067). August 24, 2026. fda.gov
3. U.S. Food and Drug Administration, CDER. Warning Letter: Royal Peptides LLC (734884). August 24, 2026. fda.gov
4. U.S. Food and Drug Administration, CDER. Warning Letter: NuScience Peptides LLC (733652). August 24, 2026. fda.gov
5. Health Law Alliance. FDA Targets GLP-1 and Peptide Compounding, Advertising and “Research Use Only” Labeling. 2026. healthlawalliance.com
6. U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. Press announcement, February 6, 2026. fda.gov
7. Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. April 30, 2026. pharmacytimes.com
8. U.S. Food and Drug Administration. Warning Letters database. fda.gov
9. Kasagga A. Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. Cureus. 2026. doi:10.7759/cureus.110657